ACADIA Pharmaceuticals Inc. beat EPS estimates 56% of the time across 16 reported quarters (9 beats, 7 misses), averaging +5.6% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $0.18 | not reported | not reported | Q2 FY26 call |
| Q1 FY26 | $0.04 | $0.02 | -50.0% | Miss | Q1 FY26 call |
| Q4 FY25 | $0.12 | $0.16 | +33.3% | Beat | Q4 FY25 call |
| Q3 FY25 | $0.14 | $0.26 | +85.7% | Beat | |
| Q2 FY25 | $0.14 | $0.16 | +14.3% | Beat | |
| Q1 FY25 | $0.10 | $0.11 | +10.0% | Beat | |
| Q4 FY24 | $0.19 | $0.17 | -10.5% | Miss | |
| Q3 FY24 | $0.13 | $0.20 | +53.9% | Beat | |
| Q2 FY24 | $0.16 | $0.20 | +25.0% | Beat | |
| Q1 FY24 | not reported | $0.10 | not reported | not reported | |
| Q4 FY23 | $0.32 | $0.28 | -12.5% | Miss | |
| Q3 FY23 | $-0.43 | $-0.40 | +7.0% | Beat |
Back to ACAD overview · ACAD holders · ACAD KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.